glp 1 review article Discovery of GLP-1–Based Drugs for the Treatment of Obesity Frontiers | The mechanism and

The authors recommend weight-based (lean body weight) dose calculation, reducing concentration as volume increases, incremental injection with aspiration, close post-block monitoring, and routine consideration of low-dose epinephrine to blunt peak plasma levels

Clinical data shows continued gradual weight loss is common, with many patients losing 0.5 to 1.5 pounds weekly at stable doses

Increased stability: Liposomal technology protects glutathione from degradation, resulting in longer-lasting effectiveness

Certain GLP-1 and GIP medications have a "major impact" on appetite and satiety, which leads to overall reduced food intake, according to the researcher